InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by King Andrew James, Directeur Scientifique. Insider active across 2 companies, notably Chinook Therapeutics, INC.. In total, 16 reports have been published. Breakdown: 0 buy · 1 sell. Total volume traded: €29k. Activity tracked since 9 November 2021. The latest transaction was disclosed on 12 February 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Declarations16 total
41,250 shares0Common StockSEC:0001193125-26-052053:0
19,157 sharesCommon StockSEC:0001209191-23-045424:0
3,333 sharesCommon StockSEC:0001209191-23-044071:0
2,500 shares@ US$0.352.0% of flowCommon StockSEC:0001209191-23-023351:0
6,803 sharesCommon StockSEC:0001209191-23-009766:0
8,333 sharesCommon StockSEC:0001209191-23-006371:0
7,500 shares@ US$0.356.2% of flowCommon StockSEC:0001209191-23-001434:0
10,152 sharesCommon StockSEC:0001209191-22-053301:0
5,000 shares@ US$0.354.3% of flowCommon StockSEC:0001209191-22-044596:0
5,000 shares@ US$0.354.4% of flowCommon StockSEC:0001209191-22-042041:0
5,000 shares@ US$0.354.8% of flowCommon StockSEC:0001209191-22-024324:0
2,500 shares@ US$13.0086.0% of flowCommon StockSEC:0001209191-22-012315:0
6,801 sharesCommon StockSEC:0001209191-22-009564:0
2,500 shares@ US$0.352.3% of flowCommon StockSEC:0001209191-22-008937:0
2,500 shares@ US$0.352.3% of flowCommon StockSEC:0001209191-21-064363:0
10,151 sharesCommon StockSEC:0001209191-21-060112:0
16 of 16 declarations
About King Andrew James
Andrew James King is the Chief Scientific Officer of Chinook Therapeutics, Inc. In this role, he is responsible for overseeing the company's research and development initiatives, ensuring that scientific projects align with strategic goals. His expertise in the scientific field is essential for guiding innovation and the development of new treatments.
